Surgery Partners recently reported fourth-quarter and full-year 2025 results showing higher sales but continued net losses, issued softer 2026 revenue guidance of US$3.35 billion to US$3.45 billion, ...

Good afternoon, and welcome to Jefferson Capital's Fourth Quarter and Full Year 2025 Conference Call. With us today are David Burton, Founder and Chief Executive Officer; and Christo Realov, Chief ...

Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces its ...